FAQs

The 10th CAR-TCR Summit Europe is the dedicated meeting for leaders advancing CAR-T, TCR-T, and next-generation cell therapies. Bringing together senior decision-makers across biotech, pharma, and academia, the summit provides an opportunity to benchmark progress, evaluate emerging technologies, and discuss the scientific, manufacturing, clinical and commercial challenges shaping the field's future.

Whether you're developing autologous, allogeneic or in vivo approaches, the meeting is designed to help you understand where the industry is heading and how peers are addressing shared challenges.

Unlike broader cell and gene therapy events, the 10th CAR-TCR Summit Europe is focused exclusively on engineered cell therapies.

This dedicated focus enables deeper discussions around:

• CAR-T and TCR-T development
• In vivo cell therapy
• Solid tumour strategies
• Manufacturing and CMC
• Regulatory considerations
• Commercialisation pathways

The result is a highly relevant agenda and audience for organisations developing or supporting cell therapy programmes.

The 10th CAR-TCR Summit Europe attracts senior leaders across the cell therapy ecosystem, including:

• Chief Scientific Officers
• Heads of Research and Translational Science
• Clinical Development Leaders
• Manufacturing and CMC Experts
• Regulatory Affairs Professionals
• Commercial and Market Access Leaders
• Academic Investigators
• Business Development and Strategy Teams

The audience spans emerging biotechs, established pharmaceutical companies, academic centres and technology providers supporting cell therapy development.

The agenda reflects the modalities and technologies generating the most interest across the industry today.

Topics include:

• In vivo CAR-T and in vivo cell therapy
• TCR-T therapies
• Multi-specific and next-generation cell therapies
• Allogeneic and off-the-shelf approachesNovel gene delivery technologies
• Cell engineering innovations
• Strategies to improve efficacy in solid tumours

The programme is designed to help attendees assess the opportunities, risks and development considerations associated with emerging approaches.

In vivo cell therapy is becoming one of the most closely watched areas in the field, and the 10th CAR-TCR Summit Europe reflects this growing momentum.

Discussions explore:

• Advances in gene delivery technologies
• Approaches to generating engineered immune cells in vivo
• Potential manufacturing and scalability advantages
• Translational and clinical development considerations
• Opportunities and challenges compared with ex vivo approaches

For organisations evaluating in vivo strategies, the summit provides a valuable opportunity to hear how developers are approaching this rapidly evolving area.

Overcoming the barriers associated with solid tumours remains a key priority for many therapy developers.

Sessions examine topics such as:

• Target selection and antigen discovery
• Tumour microenvironment challenges
• Cell trafficking and persistence
• Multi-target and armoured cell therapies
• Safety and toxicity considerations
• Clinical development strategies for solid tumours

The objective is to share lessons learned and explore the approaches showing the greatest promise for improving patient outcomes.

Manufacturing remains one of the most critical factors influencing the scalability and commercial viability of cell therapies.

Attendees can expect discussions covering:

• Process development and optimisation
• Automation and closed-system manufacturing
• Analytics and characterisation
• Quality and comparability
• Supply chain considerations
• Manufacturing scale-up strategies
• Next-generation production technologies

These discussions are designed to support organisations moving from early development towards commercial readiness.

As more cell therapies progress towards approval, commercialisation planning has become increasingly important.

The summit provides opportunities to discuss:

• Launch preparation
• Market access strategy
• Reimbursement considerations
• Treatment centre adoption
• Operational readiness
• Manufacturing-commercial alignment

The aim is to help organisations understand the requirements for successful commercialisation while learning from peers further along the development pathway.

TCR-T developers face many of the same development and commercialisation challenges as CAR-T companies, alongside modality-specific opportunities and considerations.

The summit provides a forum to discuss:

• Target discovery and validation
• Clinical development strategies
• Manufacturing requirements
• Emerging technologies
• Regulatory considerations
• Lessons learned from across the TCR-T landscape

This enables teams to benchmark their progress against the wider field while identifying opportunities for collaboration and innovation.

Allogeneic therapies continue to attract significant interest due to their potential to improve scalability and patient access.

The agenda explores:

• Clinical progress across allogeneic platforms
• Manufacturing advantages and challenges
• Persistence and durability considerations
• Gene editing technologies
• Regulatory perspectives
• Commercial implications of off-the-shelf approaches

These discussions help attendees assess the evolving role of allogeneic therapies within the broader cell therapy ecosystem.

The regulatory environment for advanced therapies continues to evolve as more products enter late-stage development and commercialisation.

The summit covers topics including:

• Clinical trial design
• Regulatory expectations
• Product characterisation
• Long-term follow-up requirements
• CMC alignment
• Real-world evidence generation

Sessions are designed to provide practical insights from organisations navigating these challenges across Europe and beyond.

One of the biggest advantages of attending a focused meeting is the opportunity to compare approaches with organisations tackling similar challenges.

Attendees can gain insight into how peers are approaching:

• Platform development
• Manufacturing strategies
• Clinical execution
• Regulatory planning
• Commercialisation readiness
• Emerging technology adoption

These conversations help teams validate their own strategies and identify new opportunities for improvement.

The summit is designed to facilitate meaningful connections among organisations developing and supporting cell therapies.

Networking opportunities include:

• Dedicated networking sessions
• Roundtable discussions
• Interactive workshops
• Exhibition hall meetings
• Informal peer-to-peer conversations

The focused audience helps ensure discussions are highly relevant and driven by shared scientific, technical and strategic priorities.

Yes. The summit brings together organisations across the full development spectrum, from early research through to commercialisation.

Attendees include companies focused on:

• Discovery and preclinical research
• Translational development
• Clinical-stage programmes
• Manufacturing scale-up
• Regulatory execution
• Product launch and commercialisation

This diverse mix helps create valuable discussions between organisations facing different but interconnected challenges.

The agenda reflects the topics having the greatest impact on the future of cell therapy development.

Key themes include:

• In vivo cell therapy
• Solid tumour innovation
• TCR-T advancement
• Manufacturing transformation and automation
• Allogeneic and off-the-shelf therapies
• Gene delivery technologies
• Clinical development strategy
• Regulatory readiness
• Commercialisation and market access

Collectively, these topics provide a comprehensive view of the scientific, technical and commercial priorities driving the next generation of CAR-T and TCR-T therapies.